Interim Results to 31 December 2010

Bioventix plc                                 

           INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2010           

Chairman's and Chief Executive's Statement

We are pleased to report the results for the six months ended 31 December 2010.
Revenues for the period of £890,256 (2009: £768,419) have continued to grow in
particular from the supply of purified antibodies to the multinational
diagnostics companies that form Bioventix's customer base. Most of this growth
has come from sales of antibodies to vitamin D which has been the subject of
intensive internal research since the summer of 2008. It is pleasing to see
that the technical success previously reported for the vitamin D project has
begun to translate into revenues for the company.

Profit before tax of £493,511 (2009:£386,210) has increased during the
half-year as a result of the growth in revenues. Cash balances at 31 December
2010 were £1,494,710 (2009:£1,475,671). In addition, the company continued with
its research and development activities aimed at augmenting the pipeline of
future antibodies for commercialisation at Bioventix's customers.

The substantial progress of Bioventix during the period is due above all to the
contributions of its employees and their commitment to Bioventix's future. On
behalf of the Board, we would like to thank them for their efforts which have
underpinned our success.

The Board of Bioventix is pleased to declare an interim dividend of 4.4p per
Ordinary share. The shares will be marked ex-dividend on 23 March 2011 and the
dividend will be paid on 28 March 2011 to shareholders on the register at close
of business on 25 March 2011.

P J Harrison
Chief Executive Officer

I J Nicholson
Non-Executive Chairman

                                 BIOVENTIX PLC                                 

                            PROFIT AND LOSS ACCOUNT                            

                for the six month period ended 31 December 2010                

                                                      Six months     Six months
                                                           ended          ended
                                                     31 Dec 2010    31 Dec 2009
                                                                               
                                                               £              £
                                                                               
TURNOVER                                                 890,256        768,419
                                                                               
Cost of sales                                           (69,369)       (99,014)
                                                                               
GROSS PROFIT                                             820,887        669,405
                                                                               
Administrative expenses                                (328,549)      (285,282)
                                                                               
Other operating income                                         -             75
                                                                               
OPERATING PROFIT                                         492,338        384,198
                                                                               
Interest receivable                                        1,173          2,012
                                                                               
Interest payable                                               -              -
                                                                               
PROFIT ON ORDINARY ACTIVITIES BEFORE TAXATION            493,511        386,210
                                                                               
Tax on profit on ordinary activities                   (111,201)       (92,997)
                                                                               
PROFIT FOR THE FINANCIAL PERIOD                          382,310        293,213
                                                                               


                                 BIOVENTIX PLC                                 

                                 BALANCE SHEET                                 

                            as at 31 December 2010                             

                                               31 Dec 2010       31 Dec 2009
                                                                            
                                                         £                 £
                                                                            
FIXED ASSETS                                                                
                                                                            
Intangible fixed assets                             60,000            80,000
                                                                            
Tangible fixed assets                              458,720           457,929
                                                                            
                                                   518,720           537,929
                                                                            
CURRENT ASSETS                                                              
                                                                            
Stocks                                             128,239           107,544
                                                                            
Debtors                                            550,310           487,910
                                                                            
Cash at bank and in hand                         1,494,710         1,475,671
                                                                            
                                                 2,173,259         2,071,125
                                                                            
CREDITORS:amounts falling due within one         (288,090)         (309,117)
year                                                                        
                                                                            
: convertible loan note                                  -       (1,071,438)
                                                                            
NET CURRENT ASSETS                               1,885,169           690,570
                                                                            
TOTAL ASSETS LESS CURRENT LIABILITIES            2,403,889         1,228,499
                                                                            
PROVISIONS FOR LIABILITIES                                                  
                                                                            
Deferred Tax                                       (7,528)          (84,867)
                                                                            
NET ASSETS                                       2,396,361         1,143,632
                                                                            
CAPITAL AND RESERVES                                                        
                                                                            
Called up share capital                            251,269             3,850
                                                                            
Capital redemption reserve                           1,231                 -
                                                                            
Share premium account                                    -           166,681
                                                                            
Other reserves                                           -           369,728
                                                                            
Profit and loss account                          2,143,861           603,373
                                                                            
SHAREHOLDERS' FUNDS                              2,396,361         1,143,632


Notes to the financial information

 1. While the interim financial information has been prepared using the
    company's accounting policies and in accordance with UK GAAP, the
    announcement does not itself contain sufficient information to comply with
    UK GAAP.
   
 2. This interim financial statement has not been audited or reviewed by the
    auditors.
   
The Directors of Bioventix plc accept responsibility for this announcement.


Bioventix plc
Peter Harrison, CEO
[phone]; [e-mail]

Keith, Bayley, Rogers & Co. Limited - PLUS Corporate Adviser
David Coffman
[phone]